<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731471</url>
  </required_header>
  <id_info>
    <org_study_id>TB019</org_study_id>
    <nct_id>NCT00731471</nct_id>
  </id_info>
  <brief_title>A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV</brief_title>
  <official_title>A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Le Dantec, Dakar, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open Phase I study of a candidate TB vaccine, MVA85A, in healthy subjects who are&#xD;
      infected with HIV. It is designed to study the safety and immunogenicity of the vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the safety of MVA85A in healthy volunteers in Senegal who&#xD;
      are infected with HIV. In phase I studies, a single vaccination with MVA85A, when&#xD;
      administered at a dose of 5 x 107pfu intradermally, has been shown to be safe in both&#xD;
      mycobacterially naïve individuals, those previously vaccinated with BCG and latently infected&#xD;
      individuals. We will use 1 x 10^8 pfu MVA85A intradermally in this study. A trial in BCG&#xD;
      vaccinated subjects showed that the higher dose (1 x 10^8 pfu MVA85A) induced a significantly&#xD;
      higher immune response but did not have a higher AE profile. In addition, because of a&#xD;
      variable immune response, the trial in HIV positive subjects in the UK is split into two&#xD;
      groups, the first getting 5 x 10^7 pfu and the second getting 1 x 10^8 pfu MVA85A. It has,&#xD;
      therefore, been decided to use the higher dose in order to maximise the immune response&#xD;
      whilst maintaining a good safety profile.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of MVA85A</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MVA85A</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 Healthy adults infected with HIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 HIV+ adults on antiretroviral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA85A</intervention_name>
    <description>Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 18 to 50 years&#xD;
&#xD;
          -  Resident in or near Dakar for the duration of the study&#xD;
&#xD;
          -  Willingness to allow the investigators to discuss the volunteer's medical history with&#xD;
             the volunteer's HIV lead physician&#xD;
&#xD;
          -  Willing to use effective contraception throughout duration of study (if female)&#xD;
&#xD;
          -  HIV antibody positive; diagnosed at least 6 months previously&#xD;
&#xD;
          -  CD4 count &gt;300&#xD;
&#xD;
          -  Arm 1: HIV viral load not &gt;100,000 copies per millilitre&#xD;
&#xD;
          -  Arm 2: Undetectable HIV viral load&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant abnormal finding on screening biochemistry or haematology&#xD;
             blood tests or on urinalysis&#xD;
&#xD;
          -  Group 1 only: Any ARV therapy within the past 6 months&#xD;
&#xD;
          -  Previous history of TB disease and/or treatment&#xD;
&#xD;
          -  Any AIDS defining illness&#xD;
&#xD;
          -  Group 1: CD4 count nadir &lt;300&#xD;
&#xD;
          -  Group 2: CD4 count nadir &lt;100&#xD;
&#xD;
          -  CXR showing TB or evidence of other active infection&#xD;
&#xD;
          -  Prior receipt of a recombinant MVA or Fowlpox vaccine&#xD;
&#xD;
          -  Use of any investigational or non-registered drug, live vaccine or medical device&#xD;
             other than the study vaccine within 30 days preceding dosing of study vaccine, or&#xD;
             planned use during the study period&#xD;
&#xD;
          -  Administration of chronic (defined as more than 14 days) immunosuppressive drugs or&#xD;
             other immune modifying drugs within six months of vaccination. (For corticosteroids,&#xD;
             this will mean prednisolone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical&#xD;
             steroids are allowed.)&#xD;
&#xD;
          -  History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine, e.g. egg products&#xD;
&#xD;
          -  Presence of any underlying disease that compromises the diagnosis and evaluation of&#xD;
             response to the vaccine (including evidence of cardiovascular disease, history of&#xD;
             cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ),&#xD;
             history of insulin requiring diabetes mellitus, any ongoing chronic illness requiring&#xD;
             ongoing specialist supervision (e.g., gastrointestinal), and chronic or active&#xD;
             neurological disease)&#xD;
&#xD;
          -  History of &gt; 2 hospitalisations for invasive bacterial infections (pneumonia,&#xD;
             meningitis)&#xD;
&#xD;
          -  Suspected or known current drug and/or alcohol abuse&#xD;
&#xD;
          -  Seropositive for hepatitis B surface antigen (HBsAg) and/ or hepatitis C (antibodies&#xD;
             to HCV)&#xD;
&#xD;
          -  Evidence of serious psychiatric condition&#xD;
&#xD;
          -  Any other on-going chronic illness requiring hospital specialist supervision&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, other than&#xD;
             HIV infection, such as asplenia&#xD;
&#xD;
          -  Evidence of hepatomegaly&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the three months&#xD;
             preceding the planned administration of the vaccine candidate&#xD;
&#xD;
          -  Pregnant/lactating female and any female who is willing or intends to become pregnant&#xD;
             during the study&#xD;
&#xD;
          -  Any history of anaphylaxis in reaction to vaccination&#xD;
&#xD;
          -  PI assessment of lack of willingness to participate and comply with all requirements&#xD;
             of the protocol, or identification of any factor felt to significantly increase the&#xD;
             participant's risk of suffering an adverse outcome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen McShane</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Souleymane Mboup</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Le Dantec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Le Dantec</name>
      <address>
        <city>Dakar</city>
        <zip>BP 7325</zip>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Senegal</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <last_update_submitted>March 25, 2011</last_update_submitted>
  <last_update_submitted_qc>March 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Helen McShane</name_title>
    <organization>University of Oxford</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

